Selected News from the Archive 2012-2016

15 Jan 2014

The NTtotalCAF ELISA is now officially available.

22 June 2012

Since its successful launch the NTCAF ELISA assay has been further developed.

The range of Neurotune’s diagnostic assay to stratify sarcopenia patients is now extended to further body fluids beyond serum. Plasma and urine may also be used for the in vitro assessment of the sarcopenia biomarker CAF (C-terminal Agrin Fragment). For more information see the revised factsheet.

Read more “Selected News from the Archive 2012-2016” →

Selected News from the Archive 2008-2010

16 December 2010

Neurotune wins the third place in the 2010 Eurecan European Venture Contest (EEVC) finals in the category healthcare companies. The finalists were selected by an international jury out of 987 applications from 24 countries.

21 October 2010

Neurotune announces positive top-line Phase IIa results for dimiracetam to treat neuropathic pain in HIV patients
Neurotune AG, a Swiss biopharmaceutical company, today announced positive top-line results from its phase IIa, safety and tolerability, study of dimiracetam (NT-11624), its lead compound for treatment-induced neuropathic pain in HIV patients receiving anti-retroviral medication.

Read more “Selected News from the Archive 2008-2010” →